Vir Biotechnology (NASDAQ:VIR)报告季度每股亏损$(0.76)，优于分析师普遍预期的$(0.87)，增长了12.64%。较去年同期的每股亏损$(0.86)提高了11.63%。公司报告季度销售额为$12.37M，超过了分析师普遍预期的$8.14M，增长了52.01%。与去年同期的销售额$16.79M相比，减少了26.29%。
以上内容来自Benzinga Earnings专栏，原文如下：
Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.87) by 12.64 percent. This is a 11.63 percent increase over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $12.37 million which beat the analyst consensus estimate of $8.14 million by 52.01 percent. This is a 26.29 percent decrease over sales of $16.79 million the same period last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.